Carcinogenicity studies were not performed with ustekinumab due to the lack of appropriate models for an antibody with no cross-reactivity to rodent IL-12/ 23 p40.
Kartsinogeensuse uuringuid ustekinumabil läbi ei viidud, kuna puuduvad sobivad mudelid antikeha jaoks, millel on ristuv reaktiivsus näriliste IL- 12/ 23 p40- ga.